Literature DB >> 28196014

Methylation of Tumor Suppressor Genes in Autoimmune Pancreatitis.

Yasuhiro Kinugawa1, Takeshi Uehara, Kenji Sano, Kazuyuki Matsuda, Yasuhiro Maruyama, Yukihiro Kobayashi, Tomoyuki Nakajima, Hideaki Hamano, Shigeyuki Kawa, Kayoko Higuchi, Noriko Hosaka, Satoshi Shiozawa, Hiroki Ishigame, Hiroyoshi Ota.   

Abstract

OBJECTIVES: Autoimmune pancreatitis (AIP) is a representative IgG4-related and inflammatory disease of unknown etiology. To clarify mechanisms of carcinogenesis resulting from AIP, we focused on methylation abnormalities and KRAS mutations in AIP.
METHODS: Six tumor suppressor genes (NPTX2, Cyclin D2, FOXE1, TFPI2, ppENK, and p16) that exhibited hypermethylation in pancreatic carcinoma were selected for quantitative SYBR green methylation-specific polymerase chain reaction in 10 AIP specimens, 10 pancreatic adenocarcinoma cases without history of AIP containing carcinoma areas (CAs) and noncarcinoma areas (NCAs), and 11 normal pancreas (NP) samples. KRAS mutation in codons 12, 13, and 61 were also investigated using direct sequencing.
RESULTS: Hypermethylation events (≥10%) were identified in NPTX2, Cyclin D2, FOXE1, TFPI2, ppENK, and p16 in 1, 2, 2, 0, 2, and 0 CA cases, respectively, but not in these 6 candidate genes in AIP, NCA, and NP. However, the TFPI2 methylation ratio was significantly higher in AIP than NCA and NP. Direct sequencing results for KRAS showed no single-point mutations in AIP.
CONCLUSIONS: These are the first studies characterizing methylation abnormalities in AIP. AIP's inflammatory condition may be related to carcinogenesis. Further study will elucidate methylation abnormalities associated with carcinogenesis in AIP.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28196014     DOI: 10.1097/MPA.0000000000000804

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

Review 1.  [IgG4-related disease : Microscopic diagnosis and differential diagnosis].

Authors:  S Detlefsen
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

Review 2.  Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.

Authors:  Mariarita Brancaccio; Francesco Natale; Geppino Falco; Tiziana Angrisano
Journal:  Genes (Basel)       Date:  2019-12-23       Impact factor: 4.096

3.  Relevance of gene mutations and methylation to the growth of pancreatic intraductal papillary mucinous neoplasms based on pyrosequencing.

Authors:  Go Asano; Katsuyuki Miyabe; Hiroyuki Kato; Michihiro Yoshida; Takeshi Sawada; Yasuyuki Okamoto; Hidenori Sahashi; Naoki Atsuta; Kenta Kachi; Akihisa Kato; Naruomi Jinno; Makoto Natsume; Yasuki Hori; Itaru Naitoh; Kazuki Hayashi; Yoichi Matsuo; Satoru Takahashi; Hiromu Suzuki; Hiromi Kataoka
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

4.  Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.

Authors:  JinHui Liu; ChengJian Ji; Yichun Wang; Cheng Zhang; HongJun Zhu
Journal:  Cancer Cell Int       Date:  2021-07-10       Impact factor: 5.722

Review 5.  Autoimmune pancreatitis and pancreatic cancer: Epidemiological aspects and immunological considerations.

Authors:  Dimitri Poddighe
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

6.  LatY136F knock-in mouse model for human IgG4-related disease.

Authors:  Kazunori Yamada; Masahiko Zuka; Kiyoaki Ito; Keishi Mizuguchi; Yasushi Kakuchi; Tamehito Onoe; Yasunori Suzuki; Masakazu Yamagishi; Shozo Izui; Marie Malissen; Bernard Malissen; Mitsuhiro Kawano
Journal:  PLoS One       Date:  2018-06-14       Impact factor: 3.240

Review 7.  Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis.

Authors:  Francesco Natale; Maria Vivo; Geppino Falco; Tiziana Angrisano
Journal:  Clin Epigenetics       Date:  2019-09-06       Impact factor: 6.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.